Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2006

View Archived Issues

GlaxoSmithKline makes strides in third quarter

Preclinical experiments display potential of PRX-302 in prostatic disease

Liraglutide added to metformin improves glucose levels in type 2 diabetes

Studies detail darunavir pharmacokinetic interactions, efficacy

Long-term activity of tipranavir measured in RESIST trials

New PDE4/TNF-alpha inhibitors emerge from Nippon Shinyaku R&D

Novel antiinfective agents disclosed in recent patent literature

First study of CK-1827452 in humans reported

Hematide-related peptide active in experimental pure red cell aplasia

Studies show benefit of predialysis erythropoietin administration

Novel HIV integrase inhibitors patented by Merck & Co.

New deadlines for VaxGen's development of anthrax vaccine

Pliva receives approvals for generic Pravastatin Tablets

Dainippon Sumitomo revises domestic development plan for AC-5216

Neurogen acquires rights to aplindore

LX-211 cleared to begin pivotal studies in uveitis

Alnylam to study ALN-RSV01 for RSV

Applied NeuroSolutions and Lilly partner in Alzheimer's disease

IC-51 safe, effective in phase III Japanese encephalitis trial

Kiadis and Celmed to merge

MLN-3897 begins phase II study for rheumatoid arthritis

GlaxoSmithKline's antimalarial development continues

Solbec updates status of Coramsine program

New trials under way for ACV-1

QVA-149 to enter clinical development in 2007

Cellegy completes sale of assets to ProStrakan

PMI-001 demonstrates positive results in rheumatoid arthritis

Heplisav superior to Engerix-B in phase II study

Daiichi Sankyo files NDA for amlodipine besylate/olmesartan medoxomil

Banyu launches Pneumovax NP in Japan

Herceptin filed in Japan for operable breast cancer with HER2 overexpression

Pediatric exclusivity for Ambien and Ambien CR